Cargando…
Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989110/ https://www.ncbi.nlm.nih.gov/pubmed/36895532 http://dx.doi.org/10.7759/cureus.34634 |
_version_ | 1784901700776099840 |
---|---|
author | Patel, Kishan Dang, Adrian Makhlouf, Mai M Raman, Alex G Abdulla, Nihal E |
author_facet | Patel, Kishan Dang, Adrian Makhlouf, Mai M Raman, Alex G Abdulla, Nihal E |
author_sort | Patel, Kishan |
collection | PubMed |
description | The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, and oral (PO) steroids, and exhibited reportable improvements with the addition of intravenous (IV) methylprednisolone to other antidiarrheal agents. We present a case of CRD in an 82-year-old female. She was initiated on chemotherapy three weeks prior and has experienced severe diarrhea since her initiation. Despite the use of first-line antidiarrheal therapies, including loperamide, diphenoxylate-atropine, and octreotide, both subcutaneously and via continuous infusion drip, no infectious cause was found. She also received the non-absorbing corticosteroid budesonide, but her diarrhea persisted. After experiencing severe hypotension and hypovolemia secondary to profuse diarrhea, she was placed on IV steroids, which quickly reduced her symptoms. The patient was then transitioned to oral steroids and discharged on a tapering regimen. We recommend using IV steroids to treat CRD if first-line therapies fail. Utilizing IV steroids efficiently and effectively can decrease the symptoms of persistent diarrhea and lead to rapid recovery. |
format | Online Article Text |
id | pubmed-9989110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-99891102023-03-08 Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report Patel, Kishan Dang, Adrian Makhlouf, Mai M Raman, Alex G Abdulla, Nihal E Cureus Internal Medicine The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, and oral (PO) steroids, and exhibited reportable improvements with the addition of intravenous (IV) methylprednisolone to other antidiarrheal agents. We present a case of CRD in an 82-year-old female. She was initiated on chemotherapy three weeks prior and has experienced severe diarrhea since her initiation. Despite the use of first-line antidiarrheal therapies, including loperamide, diphenoxylate-atropine, and octreotide, both subcutaneously and via continuous infusion drip, no infectious cause was found. She also received the non-absorbing corticosteroid budesonide, but her diarrhea persisted. After experiencing severe hypotension and hypovolemia secondary to profuse diarrhea, she was placed on IV steroids, which quickly reduced her symptoms. The patient was then transitioned to oral steroids and discharged on a tapering regimen. We recommend using IV steroids to treat CRD if first-line therapies fail. Utilizing IV steroids efficiently and effectively can decrease the symptoms of persistent diarrhea and lead to rapid recovery. Cureus 2023-02-04 /pmc/articles/PMC9989110/ /pubmed/36895532 http://dx.doi.org/10.7759/cureus.34634 Text en Copyright © 2023, Patel et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Patel, Kishan Dang, Adrian Makhlouf, Mai M Raman, Alex G Abdulla, Nihal E Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title | Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title_full | Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title_fullStr | Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title_full_unstemmed | Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title_short | Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report |
title_sort | intravenous steroids for refractory chemotherapy-related diarrhea: a case report |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989110/ https://www.ncbi.nlm.nih.gov/pubmed/36895532 http://dx.doi.org/10.7759/cureus.34634 |
work_keys_str_mv | AT patelkishan intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport AT dangadrian intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport AT makhloufmaim intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport AT ramanalexg intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport AT abdullanihale intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport |